Overview
Pitavastatin is a third-generation synthetic statin developed to manage elevated cholesterol levels and reduce the risk of cardiovascular events. As an HMG-CoA reductase inhibitor, it competitively blocks the enzyme responsible for cholesterol synthesis in the liver. Approved in Japan (2003) and later in the US (2009), it is marketed under the brand name Livalo. Compared to older statins like atorvastatin, pitavastatin offers advantages such as minimal drug interactions due to limited cytochrome P450 metabolism and a lower risk of muscle-related side effects. It is commonly prescribed for patients with primary hyperlipidemia or mixed dyslipidemia.
Physical and Chemical Properties
Pitavastatin exists as a white to off-white crystalline powder with a molecular weight of 421.47 g/mol. Its melting point ranges between 160-162°C, and it demonstrates solubility in organic solvents like dimethyl sulfoxide (DMSO) and methanol but limited solubility in water. The compound's stability is influenced by environmental factors; it degrades under prolonged exposure to light, heat, or humidity. Analytical methods such as HPLC and LC-MS are typically employed to assess its purity, which should exceed 98% for pharmaceutical use. The molecular structure includes a fluorophenyl group, contributing to its potent lipid-lowering effects.
Main Applications
Pitavastatin is primarily used to treat hypercholesterolemia by lowering low-density lipoprotein (LDL) cholesterol and triglycerides while increasing high-density lipoprotein (HDL) levels. Clinical studies highlight its efficacy in reducing atherosclerotic plaque formation and preventing strokes or heart attacks in high-risk patients. Beyond cardiovascular care, research explores its potential in anti-inflammatory therapies and neuroprotection, though these applications remain investigational. The drug is available in tablet form (1 mg, 2 mg, and 4 mg doses) and is often preferred for patients intolerant to other statins due to its favorable safety profile.
Safety and Storage
Pitavastatin is generally well-tolerated, but adverse effects may include myopathy, elevated liver enzymes, or gastrointestinal discomfort. Regular monitoring of liver function and creatine kinase levels is recommended during treatment. It is contraindicated in pregnant women due to risks of fetal harm. For storage, pitavastatin should be kept in sealed containers at 2-8°C, away from light and moisture. Bulk pharmaceutical quantities require controlled environments to prevent degradation. Safety data sheets (SDS) must be consulted for handling procedures, including the use of personal protective equipment (PPE) to avoid inhalation or skin contact.
B2B Procurement Guide
When sourcing pitavastatin for pharmaceutical manufacturing, buyers should prioritize suppliers with certifications such as GMP, ISO, or FDA/EMA compliance. Key specifications include purity (≥98%), residual solvent levels, and absence of genotoxic impurities. Pricing varies based on quantity and supplier reputation, with reference ranges of $50-$200 per gram. Procurement contracts should outline testing protocols (e.g., COA validation) and logistics for temperature-sensitive shipping. Emerging markets in Asia and Europe offer competitive alternatives, but regulatory alignment with the target market is critical.
Related Manufacturers
- 主营：匹伐他汀、莪术二酮、人参皂苷rc
- 主营：对照品、中药对照药材、中药农残空白基质、药品检测标准品、药物杂质标准品、分析标准品、金属离子标准溶液、食品检测标准物质、有机检测标准溶液、PH标准溶液、熔点标准品、国家标准物质、仪器检测校准品、滴定溶液、指示液、缓冲液、电导率溶液、比色液
- 主营：匹伐他汀内酯、白蜡树素、百两金素、半齿泽兰素
- 主营：对照品、当归酸酐、佛手柑内酯、标准品、新当归内酯、补骨脂甲素、补骨脂乙素、羟基芍药苷、阿魏酸松柏酯、水合氧化前胡素、豆甾醇葡萄糖苷